37,183 Shares in Mirum Pharmaceuticals, Inc. $MIRM Purchased by Man Group plc

Man Group plc acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 37,183 shares of the company’s stock, valued at approximately $4,353,000. Man Group plc owned approximately 0.06% of Mirum Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MIRM. BlackRock Inc. purchased a new stake in shares of Mirum Pharmaceuticals during the second quarter valued at approximately $513,945,000. Nan Fung Trinity HK Ltd. boosted its position in Mirum Pharmaceuticals by 45.6% in the fourth quarter. Nan Fung Trinity HK Ltd. now owns 227,479 shares of the company’s stock worth $17,969,000 after purchasing an additional 71,214 shares during the last quarter. Emerald Advisers LLC boosted its position in Mirum Pharmaceuticals by 8.2% in the first quarter. Emerald Advisers LLC now owns 397,263 shares of the company’s stock worth $36,699,000 after purchasing an additional 30,129 shares during the last quarter. SBI Okasan Asset Management Co.Ltd. bought a new position in Mirum Pharmaceuticals in the 4th quarter valued at $1,283,000. Finally, Rice Hall James & Associates LLC bought a new position in Mirum Pharmaceuticals in the 2nd quarter valued at $12,956,000.

Insiders Place Their Bets

In other news, CEO Christopher Peetz sold 20,000 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $98.92, for a total value of $1,978,400.00. Following the completion of the transaction, the chief executive officer directly owned 194,309 shares of the company’s stock, valued at $19,221,046.28. This trade represents a 9.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Jolanda Howe sold 40,000 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total value of $4,000,000.00. Following the completion of the transaction, the senior vice president owned 1,274 shares of the company’s stock, valued at approximately $127,400. This trade represents a 96.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 103,156 shares of company stock worth $10,888,362 over the last 90 days. Corporate insiders own 8.32% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently commented on MIRM shares. Weiss Ratings upgraded Mirum Pharmaceuticals from a “sell (d-)” rating to a “sell (d)” rating in a research note on Thursday, August 6th. Wolfe Research assumed coverage on shares of Mirum Pharmaceuticals in a report on Tuesday, May 19th. They set an “outperform” rating and a $145.00 price objective for the company. Citizens Jmp restated a “market outperform” rating and set a $137.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday. HC Wainwright dropped their target price on shares of Mirum Pharmaceuticals from $185.00 to $140.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. Finally, TD Cowen dropped their target price on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating on the stock in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Mirum Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $137.31.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $97.46 on Monday. The company’s 50 day moving average is $110.63 and its 200-day moving average is $101.80. Mirum Pharmaceuticals, Inc. has a 12-month low of $63.23 and a 12-month high of $130.00. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. The firm has a market cap of $6.33 billion, a P/E ratio of -6.70 and a beta of 0.52.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The business had revenue of $176.24 million during the quarter, compared to the consensus estimate of $166.33 million. During the same period last year, the business posted ($0.12) earnings per share. The firm’s quarterly revenue was up 37.9% on a year-over-year basis. Sell-side analysts predict that Mirum Pharmaceuticals, Inc. will post -1.31 earnings per share for the current year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.